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Background: Some pediatric tertiary care centres in North America supplement conventional care with
complementary therapies, together known as pediatric integrative medicine (PIM). Evidence to support
the safety and efﬁcacy of PIM is emerging, but the cost-effectiveness of an inpatient PIM service has yet
to be assessed.
Methods/Design: This study is a pragmatic cluster controlled clinical trial. Usual care will be compared to
usual care augmented with PIM in three pediatric divisions; oncology, general medicine, and cardiology
at one large urban tertiary care Canadian Children's Hospital. The primary outcome of the feasibility
study is enrolment; the primary outcome of the main study is cost-effectiveness. Other secondary
outcomes include the prevalence and severity of key symptoms (i.e. pain, nausea/vomiting and anxiety),
efﬁcacy of PIM interventions, patient safety, and parent satisfaction.
Discussion: This trial will be the ﬁrst to evaluate the comparative effectiveness, both clinical and cost, of a
PIM inpatient service. The evidence from this study will be useful to families, clinicians and decision
makers, and will describe the clinical and economic value of PIM services for pediatric patients admitted
to hospital.
© 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).hra), mschlege@ualberta.ca
rtﬁeld@albertahealthservices.
n), Arto.ohinmaa@ualberta.ca
son), mspavor@ualberta.ca
n open access article under the CC1. Introduction
When complementary therapies, for which there is evidence of
safety and effectiveness, are combinedwith conventional medicine,
it is known as “integrative medicine” [1]. Use and acceptance of
integrative therapies among patients is high, especially in those
with chronic conditions, and account for nearly US$34 billion inBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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children and their parents seek non-pharmacological approaches
tomanaging their health, interventions perceived as being effective
and safe are increasingly being sought, despite the relative paucity
of high quality published medical literature supporting such ther-
apies. Additionally, the cost-effectiveness of integrative medicine
programs has not been systematically studied in pediatrics. Dozens
of North American pediatric hospitals have begun to offer pediatric
integrative medicine (PIM) services, and are providing PIM thera-
pies to inpatients [3,4]. PIM may be helpful in treating highly
prevalent symptoms for hospitalized children, such as pain, nausea/
vomiting, and anxiety (PNVA), for which pharmacotherapy is
available, but not always effective.
Pediatric inpatients commonly experience PNVA during their
stay in hospital [5e7]. Poorly managed PNVA can decrease
compliance with conventional care, prolong recovery time, and
increase costs to the health care system [8e10]. Pain is common in
hospitalized children, and despite efforts to improve pain man-
agement, under-recognition and under treatment of pain persist
[11,12]. Nausea and vomiting are also commonly experienced, and
occur in up to 80% of post-operative and up to 90% of oncology
patients [9,13e15]. Though improvements in chemotherapy and
anti-emetics have been achieved, nausea and vomiting still are
known predictors of increased length of stay (LOS) in hospital, and
severe nausea and vomiting can lead to a postponement or
discontinuation of chemotherapy [9,16]. Anxiety is not only asso-
ciated with pain and nausea/vomiting, but also with hospitalization
experiences and procedures. Untreated anxiety negatively affects
physical and psychological health [17e20].
Pharmacotherapy to manage PNVA has varying levels of effec-
tiveness and can be associated with adverse effects, which may be
minor (e.g., sedation) or serious (e.g., respiratory depression) [21].
Children and their parents/caregivers may wish to explore non-
pharmacological options to augment care. Various complemen-
tary therapies have demonstrated safety and efﬁcacy for pain
[22e29], nausea and vomiting [25,30], and anxiety [31,32], but
robust pediatric data are lacking.
2. Objectives
This study investigates if PIM therapies (such as acupuncture,
massage or reiki), in addition to usual inpatient pediatric care, are
feasible and cost-effective for a large tertiary care centre, and
effective and safe for patients. The effects on outcomes such as
patient symptoms, safety, satisfaction, length of stay and costs will
be measured and we will identify which of these key outcomes are
most affected, for which children, and why. Through mixed
methods research (qualitative, quantitative, and health economics),
we will also develop a thorough understanding of why parents
choose PIM services and health care providers' experience of the
PIM service. Our study is intended to provide the rigorous evidence
that health care decision-makers need to determine if and when
integrative medicine should be offered to childrenwhile they are in
hospital, and will help address an important gap in public health
policy and practice.
3. Methods
3.1. Design
Complementary therapies are often administered as complex
interventions, comprised of a number of separate elements that
may interact with each other. A study design suitable for evaluating
complex interventions is the pragmatic clinical trial (PCT) [33e35].
As such, we are conducting a 2-arm, cluster controlled, mixedmethods pragmatic trial. Each consenting participating Division is
assigned to receive PIM services or not in an ABA design, where A is
usual care and B is usual care augmented by PIM therapies.
Our design has been informed by two of the largest inpatient
integrative medicine programs in the United States. We have cho-
sen target symptoms and complementary therapies based on the
successful and long-standing model built by our collaborator, Dr.
Tim Culbert, Medical Director, PIM Service, Children's Hospitals and
Clinics of Minnesota. We have chosen cost-effectiveness as our
primary outcome based on compelling preliminary data from the
adult inpatient setting, suggesting that for every $1 spent on inte-
grative therapies, $1.80 is saved (personal communication, Dr. Jeff
Dusek, Research Director, Institute of Health and Healing, Abbott
Northwestern Hospital).
3.2. Setting
This trial is being conducted at the Stollery Children's Hospital,
in Edmonton, Alberta, Canada. We approached many clinical di-
visions regarding their interest and readiness to participate in our
trial. We subsequently partnered with three admitting Divisions:
pediatric oncology, general pediatrics and pediatric cardiology.
3.3. Participants: eligibility, screening, and enrolment
Inclusion criteria for study enrolment are: (i) admission to a
participating Division; (ii) caregiver communication in English; (iii)
caregiver is available to participate; (iv) caregiver consent/child
assent. Patients are eligible if they arrive in the ward as a new
admission during the study, or if they are currently admitted when
the study begins collecting data from their Division. Two additional
inclusion criteria are applied at the time of data analysis: (v) length
of stay in the participating Division is between 2 and 30 days and
(vi) age on admission is less than 16 years. If, at admission, patients
are expected to be discharged within 2 days or to stay longer than
30, they will not be approached by the research team.
Length of stay is measured from admission to transfer to ICU,
discharge, or death. In the event of a transfer to ICU, data collection
is to be paused for that case, and resumed when the patient is
transferred back to the admitting Division.
3.4. Blinding and bias
Due to the nature of the intervention, and ethical considerations
around parental consent for PIM therapies to be delivered, it is
impossible to blind participants, providers or data collection re-
searchers to the intervention. However, we are taking extra pre-
cautions to minimize bias with the following:
1) Careful documentation of participant characteristics in order to
control for differences between groups, including previous
complementary therapy use, as well as beliefs/expectations
regarding complementary therapies.
2) Use of an active control group with similar baseline de-
mographics and disease states, being treated in the same Divi-
sion as the intervention group.
3) Use of cost-effectiveness as an outcome. A conservative
assumption is that the patient and provider may be biased to-
wards complementary therapies, leading to their increased use,
symptomatic improvement, and satisfaction with care. This will
be balanced by measurement of cost-effectiveness, rather than
satisfaction or effectiveness alone, as increased use generates
increased PIM service related costs.
4) Use of an ABA design. It is possible that the study may bias
providers and patients to have a heightened awareness of
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intervention will allow us to ensure that no changes in usual
care resulted from having symptom awareness augmented with
PIM services.
5) Analyzing groups under an intention-to-treat analysis will
reduce bias due to systematic differences between individuals
who received the intervention and those who did not.3.5. Control and intervention groups
3.5.1. Control
The control group will receive usual care, including pharmaco-
therapy, and will be followed as per usual hospital standards in
each Division. No complementary therapies under study will be
available for inpatients at our hospital during this time. Nursing
staff currently make clinical assessments of PNVA during each shift
as part of usual care, however, standardized outcome measures are
only used for pain in our hospital. Literature supports that PNVA are
underreported and under treated [12,36e38]. As such, our research
nurse will record PNVA using validated outcomemeasures daily, on
week days only, for all participants.3.5.2. Intervention
The intervention group will receive usual care augmented by
consultation with the PIM service and selected PIM therapies. Pa-
tients are eligible if they are symptomatic for PNVA or other dis-
tressing symptom; they are referred to the PIM service by the
research nurse. Upon referral to the PIM service, patients is
assessed by a clinical nurse who is speciﬁcally trained for this trial
and who has in-depth knowledge of the complementary therapies
offered (acupuncture, reiki and massage therapy). The clinical
nurse will discuss these three complementary therapies and a de-
cisionwill be made by consensus among the patient, the family and
the research nurse, in consultation with one of our Hospital's pe-
diatric integrative medicine specialists (SV, HJ) as needed. This
decision will be based on the child's needs and preferences, and in
light of best evidence and therapeutic indications/contra-
indications, for one or more complementary therapies. The com-
plementary therapy providers have been credentialed by our
Children's Hospital based on their training and expertise. Dose,
duration, and frequency of PIM therapies are individualized in
accordance with real world practice and offered Monday to Friday,
usually in the afternoons/early evening based on the availabilities
of the patients, caregivers, and therapists.
In accordance with the pragmatic nature of this trial, children
will be permitted to choose more than one PIM therapy during the
course of their hospital stay, although they will be encouraged to
use them in sequence rather than in parallel; timing depends on the
child's condition and the complementary therapy providers' clin-
ical judgement and availability. Each patient will be followed until
their symptoms resolve; re-consultation with the PIM service for a
new or recurring target symptom is permissible and will be offered
on an as-needed basis. If patients are transferred into the pediatric
intensive care unit, the PIM service is discontinued, but may be
resumed, if appropriate, once the patient is transferred back to the
participating pediatric Division. A diagram of patient ﬂow through
the study is presented in Fig. 1.3.6. Primary outcome
The primary outcome of the feasibility study is enrolment. The
primary outcome of the main study is cost-effectiveness.3.7. Secondary outcomes
The tools and timelines for all secondary outcomes are detailed
in Table 1.
3.7.1. PNVA symptoms
Comparative effectiveness will be assessed by changes in PNVA
scores in the intervention and control groups. Patient pain will be
measured in pre-verbal children using the Faces, Legs, Activity, Cry,
Consolability [39] (FLACC) tool and for verbal children with the
Faces Pain Scale-Revised [40] (FPS-R). Nausea and anxiety scores
will be collected from verbal children only using Baxter Retching
Faces [41] (BARF) and Pediatrics Anxiety Faces Scale [42] (PAFS),
respectively. Vomiting will be measured by incidence of vomiting
each day.
A research nurse will measure symptoms each morning
(Monday to Friday). For patients in the intervention arm, their
symptoms will by measured again, both immediately prior to and
immediately post PIM therapy intervention. These two additional
symptom severity measurements will be assessed on a numerical
rating scale (NRS) out of ten.
3.7.2. Safety
Incidence of patient and parent reported adverse events (AEs)
pertaining to usual care and speciﬁcally to complementary therapy
use will be presented. Parent reported AEs will be measured with
the BC Children's Hospital patient safety questionnaire [43]. We
will also apply the Canadian Pediatric Trigger Tool (CPTT) [44]
retrospectively to identify and assign potential AEs to all cases.
3.7.3. Parent satisfaction and anxiety
Parent satisfaction will be assessed quantitatively at discharge
using our Hospital's standardized satisfaction survey, verbatim. We
did not alter this tool nor verify its validation. Satisfaction will be
compared between the two study arms. Changes from baseline to
follow up in parental state and trait anxiety will be reported and
compared. Parent anxiety will be measured using the State-Trait
anxiety Inventory [45].
3.7.4. Economic analysis
Patient length of stay in hospital, resource utilization and costs
will be compared between study arms. The hospital cost will be
calculated using patient level itemized procedure and cost esti-
mates from the hospital costing database. PIM related costs will be
added to the costs based on the individual utilization of the ser-
vices, the actual fees for those services, and health care utilization
and costs after hospital episode will be estimated based on parent
follow up survey 30 days after discharge. All costs will be shown in
2015 Canadian dollar values.
3.7.5. Baseline and other trial data
Patient and caregiver demographic informationwill be collected
at baseline along with data regarding history of complementary
therapy use. Pediatric Quality of Life Inventory version 4.0 (PedsQL
4.0) questionnaire [46] (child and parent proxy version for
nonverbal children) will be collected at admission. Medication
intake and PIM service therapy consultations and utilizationwill be
measured daily (M-F). Other symptoms that may trigger a PIM
consult will be captured using the Measure Yourself Medical
Outcome Proﬁle (MYMOP) [47]. A chart review for diagnoses,
treatments and discharge data will be done at discharge. Follow up
data on patient symptom prevalence, and outpatient complemen-
tary therapy and other health care utilization will be assessed by
telephone at follow up, 30 days after discharge.
Fig. 1. CONSORT Patient ﬂow chart showing patient ﬂow through each of the control (A) and intervention (B) trial arms. Data are collected in an ABA sequence.
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We will report results of decision-making and parent satisfac-
tion that stem from one-on-one telephone interviews. Results will
be compared between parents of patients who are offered and
utilized PIM, and those who are only offered conventional care.
Results from one-on-one, semi-structured interviews with health
care providers and with CAM providers will be presented to explain
their experiences with providing care to patients.
3.8. Assessment timeline
Datawill be collected at baseline (t0), daily during admission (t2-
30), at discharge (t31) and by telephone at follow up (t32) which is 30days post-discharge. An overview of timelines and outcome mea-
sures is shown in Table 1.
3.9. Sample size calculation and recruitment
Since this study is one of the ﬁrst of its kind, data for sample size
calculations and for minimally important differences in patient
symptoms and length of stay are sparse. The feasibility assessment
will inform future sample size calculations in this study population.
We hope to enroll 50 children in each arm (control and interven-
tion) of pediatric oncology and cardiology, and 100 in each arm of
general pediatric inpatients.
In order to reach saturation of qualitative data, we will conduct
Table 1
PIM trial outcome measures, data instruments and timelines.
Data collection instrument Baseline and day 1 (t0) Daily during admission
(t2-30)
Discharge (t31) Telephone follow up
(t32)
Study group Control Intervention Control Intervention Control Intervention Control Intervention
Screening/Consent X X
Baseline Demographics X X
Daily Assessment X X X X
Medication X X X X X X
Pain (FPS_R) X X X X
Nausea (BARF) X X X X
Anxiety (PAFS) X X X X
Anxiety (NRS) X X X X
General Symptom (NRS) X X X X
NRS Pre-post CAM X X
MYMOP X X
CAM Therapy Intake, Interruption and Follow Up X X
PIM Referral, consult and AE X X
Parent STAI X X X X X X
Parent Peds QL X X X X X X
Patient Peds QL X X X X X X
Chart Review X X
Patient Safety X X
Parent Satisfaction X X
Follow Up Questionnaire X X
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division with parents who choose PIM and with parents offered
only usual care, for a total of approximately 60 interviews.
Approximately 10 interviews will be conducted with health care
providers and 10 interviews with CAM providers in the third year of
the project.3.10. Data management
Raw data forms will be secured and stored in the Women and
Children's Health Research Institute (WHCRI) ofﬁces at the Uni-
versity of Alberta. Study data are entered and managed using
REDCap (Research Electronic Data Capture) hosted at the University
of Alberta [48]. These data will be accessible only to the authors
listed on this protocol.3.11. Quantitative data analysis
Since there is such variety between each admitting Division,
each will be analyzed separately. The quantitative effectiveness
outcomes will be pursued under an intention-to-treat and a per
protocol analysis.
Baseline data on all enrolled patients will be summarized using
descriptive statistics and will be compared in three ways: those
enrolled and those who refused to participate, usual care pre and
post intervention (comparing the two ‘A’ arms of the ABA design)
and, treatment and control groups (A vs B). Feasibility will be
analyzed to compare all eligible patients with those who were
enrolled and those with complete measurements collected.
Comparison tests of two independent means or proportions will
be performed on the symptom scores, safety outcomes, quality of
life and parental satisfaction outcomes. The comparisons will be
made with independent t-tests, analysis of variance or with the
non-parametric equivalents as appropriate. c2 analysis, with
Fisher's exact test as necessary, or logistic regression will be per-
formed on dichotomous outcomes, such as parental satisfaction
and patient safety, allowing us to control for confounders identiﬁed
a priori.
The analysis of the cost data will be done using different
regression methods estimating the difference in total costsbetween the two study arms. Decision analysis modeling will be
used to estimate the Incremental Cost-Effectiveness Ratio (ICER)
with 95% conﬁdence interval, and probabilistic sensitivity analysis
and treatment acceptability curve analysis will be used to support
decision making.
All descriptive and inferential statistics will be two-tailed and
reported with 95% conﬁdence intervals and p-values at a ¼ 0.05
level of signiﬁcance.
3.12. Qualitative data analysis
Analysis of all one-on-one interviews will follow a constant
comparison technique that will lead to theory or model
development.
4. Discussion
To our knowledge, this landmark study is the ﬁrst comparative
effectiveness trial to assess the impact of PIM as adjunctive care for
pediatric inpatients. We have chosen common symptoms that
negatively affect the health of the majority of pediatric inpatients.
This study will help describe the complex decision-making asso-
ciated with use of complementary PIM therapies and will rigour-
ously assess the impact of hospital-based complementary
treatments on patient symptoms, safety, quality of life, and parent
and health care provider satisfaction. Most importantly, this study
will provide valuable evidence to health care administrators and
policy makers on the cost-effectiveness of providing pediatric
integrative medicine services to inpatients in a North American
tertiary care centre.
4.1. Strengths
A key strength of this study lies in the pragmatic design of the
trial, which will enable us to draw conclusions while accommo-
dating the diversity of the three Divisions studied. Because we are
striving to describe the effects of complementary therapies under
typical conditions, rather than ideal conditions, the pragmatic
design is a suitable method that can inform decision makers on
additional options for care [49]. Close monitoring of baseline
S. Vohra et al. / Contemporary Clinical Trials Communications 5 (2017) 12e18 17patient characteristics as well as daily pharmacologic and non-
pharmacologic treatments allows for careful control of patient
health outcome predictors, maximizing the accuracy of the treat-
ment effect measures. Lastly, the external validity and generaliz-
ability to other children's hospitals is high. We have veriﬁed that
the patient demographics, illness, types of treatment, and patient
outcomes of children seen at our hospital compare to others in
North America [50,51]. Furthermore, they reﬂect national averages
for reasons for admission and length of stay when compared with
Canadian Institute for Health Information database (personal
communication, Donna Scheurman, Clinical Information Coordi-
nator, Stollery Children's Hospital).4.2. Limitations
Measurement bias in symptom scores may occur in our study
because patients and researchers are not blinded to the interven-
tion. This may exaggerate symptom improvements when receiving
PIM therapies, and likewise underreport improvements in the
control groups. Reporting cost-effectiveness as our primary
outcome mitigates this bias.
Because it is impossible to blind participants to their allocation
group, there is potential for response bias in symptom scores. It is
possible that if patients know there are additional therapies being
offered, they may be more inclined to report more severe symp-
toms. Nonetheless, even if a patient's knowledge of their treatment
in a pragmatic trial was a part of their therapy, this toowould be the
case in clinical practice [52].Trial status
Participant recruitment commenced in January 2013, and as of
March 2016, was ongoing. Data collection was approximately 70%
complete at the time of manuscript submission. This protocol is
version 2 and was prepared in accordance with the SPIRIT 2013
checklist.Ethics
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